Mechanism of Generation of Therapy Related Leukemia in Response to Anti-topoisomerase II Agents

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2012 Jul 26

PMID 22829791

Citations 61

Authors

Ian G Cowell

Caroline A Austin

Affiliations

Soon will be listed here.

Abstract

Type II DNA topoisomerases have the ability to generate a transient DNA double-strand break through which a second duplex can be passed; an activity essential for DNA decatenation and unknotting. Topoisomerase poisons stabilize the normally transient topoisomerase-induced DSBs and are potent and widely used anticancer drugs. However, their use is associated with therapy-related secondary leukemia, often bearing 11q23 translocations involving the MLL gene. We will explain recent discoveries in the fields of topoisomerase biology and transcription that have consequences for our understanding of the etiology of leukemia, especially therapy-related secondary leukemia and describe how these findings may help minimize the occurrence of these neoplasias.

Citing Articles

Bioinformatic Analysis of Topoisomerase IIα Reveals Interdomain Interdependencies and Critical C-Terminal Domain Residues.

Endsley C, Moore K, Townsley T, Durston K, Deweese J Int J Mol Sci. 2024; 25(11).

PMID: 38891861 PMC: 11172036. DOI: 10.3390/ijms25115674.

Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti-cancer drug etoposide.

Cowell I, Austin C FEBS Open Bio. 2024; 14(6):1001-1010.

PMID: 38531625 PMC: 11148113. DOI: 10.1002/2211-5463.13799.

Actions of a Novel Bacterial Topoisomerase Inhibitor against Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks.

Dauda S, Collins J, Byl J, Lu Y, Yalowich J, Mitton-Fry M Int J Mol Sci. 2023; 24(15).

PMID: 37569485 PMC: 10419083. DOI: 10.3390/ijms241512107.

MSN8C: A Promising Candidate for Antitumor Applications as a Novel Catalytic Inhibitor of Topoisomerase II.

Ou J, Huang W, Liu X, Dai G, Wang L, Huang Z Molecules. 2023; 28(14).

PMID: 37513470 PMC: 10383749. DOI: 10.3390/molecules28145598.

Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy.

Araie H, Arai Y, Kida M, Aoki J, Uchida N, Doki N Ann Hematol. 2023; 102(10):2879-2893.

PMID: 37477669 PMC: 10492731. DOI: 10.1007/s00277-023-05356-6.

References

Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z . Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported.... Leukemia. 2002; 16(12):2366-78. DOI: 10.1038/sj.leu.2402713. View

Osborne C, Chakalova L, Brown K, Carter D, Horton A, Debrand E . Active genes dynamically colocalize to shared sites of ongoing transcription. Nat Genet. 2004; 36(10):1065-71. DOI: 10.1038/ng1423. View

McNamara S, Wang H, Hanna N, Miller Jr W . Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol. 2008; 28(6):2066-77. PMC: 2268389. DOI: 10.1128/MCB.01576-07. View

Toyoda E, Kagaya S, Cowell I, Kurosawa A, Kamoshita K, Nishikawa K . NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008; 283(35):23711-20. PMC: 3259784. DOI: 10.1074/jbc.M803936200. View

Scharf S, Zech J, Bursen A, Schraets D, Oliver P, Kliem S . Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene. Oncogene. 2006; 26(10):1361-71. DOI: 10.1038/sj.onc.1209948. View

Voltz R, Starck M, Zingler V, Strupp M, Kolb H . Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler. 2004; 10(4):472-4. DOI: 10.1191/1352458504ms1047cr. View

Gao H, Huang K, Yamasaki E, Chan K, Chohan L, Snapka R . XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999; 96(21):12168-73. PMC: 18430. DOI: 10.1073/pnas.96.21.12168. View

Barthelmes H, Grue P, Feineis S, Straub T, Boege F . Active DNA topoisomerase IIalpha is a component of the salt-stable centrosome core. J Biol Chem. 2000; 275(49):38823-30. DOI: 10.1074/jbc.M007044200. View

Haffner M, Aryee M, Toubaji A, Esopi D, Albadine R, Gurel B . Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010; 42(8):668-75. PMC: 3157086. DOI: 10.1038/ng.613. View

10.

Meaburn K, Misteli T, Soutoglou E . Spatial genome organization in the formation of chromosomal translocations. Semin Cancer Biol. 2006; 17(1):80-90. PMC: 1805052. DOI: 10.1016/j.semcancer.2006.10.008. View

11.

Mistry A, Felix C, Whitmarsh R, Mason A, Reiter A, Cassinat B . DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med. 2005; 352(15):1529-38. DOI: 10.1056/NEJMoa042715. View

12.

Mao Y, Desai S, Ting C, Hwang J, Liu L . 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem. 2001; 276(44):40652-8. DOI: 10.1074/jbc.M104009200. View

13.

Le Deley M, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C . Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2006; 25(3):292-300. DOI: 10.1200/JCO.2006.05.9048. View

14.

Super H, McCabe N, Thirman M, Larson R, Le Beau M, Pedersen-Bjergaard J . Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993; 82(12):3705-11. View

15.

Schoenfelder S, Sexton T, Chakalova L, Cope N, Horton A, Andrews S . Preferential associations between co-regulated genes reveal a transcriptional interactome in erythroid cells. Nat Genet. 2009; 42(1):53-61. PMC: 3237402. DOI: 10.1038/ng.496. View

16.

Swift L, Rephaeli A, Nudelman A, Phillips D, Cutts S . Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006; 66(9):4863-71. DOI: 10.1158/0008-5472.CAN-05-3410. View

17.

Ottone T, Hasan S, Montefusco E, Curzi P, Mays A, Chessa L . Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer. 2008; 48(3):213-21. DOI: 10.1002/gcc.20633. View

18.

Cuvier O, Hirano T . A role of topoisomerase II in linking DNA replication to chromosome condensation. J Cell Biol. 2003; 160(5):645-55. PMC: 2173373. DOI: 10.1083/jcb.200209023. View

19.

Stanulla M, Wang J, Chervinsky D, Thandla S, Aplan P . DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol. 1997; 17(7):4070-9. PMC: 232260. DOI: 10.1128/MCB.17.7.4070. View

20.

Lovett B, Lo Nigro L, Rappaport E, Blair I, Osheroff N, Zheng N . Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci U S A. 2001; 98(17):9802-7. PMC: 55533. DOI: 10.1073/pnas.171309898. View